Evidence map›Paper›PMID 36309561›Full record

ArticleLeukemia2023

UTX loss alters therapeutic responses in KMT2A-rearranged acute myeloid leukemia.

Xinyue Zhou, Pengcheng Zhang, Sajesan Aryal, Lixia Zhang, Rui Lu

Abstract read
In one paragraph

Article in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Dissecting Epigenetic Drug Response Mechanisms Using CRISPR Knockout Screens.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Targeting the deubiquitinaseOncology reports · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Xinyue ZhouDepartment of Medicine, Division of Hematology/Oncology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, 35294, USA.ORCID http://orcid.org/0000-0002-3242-1518
Pengcheng ZhangDepartment of Medicine, Division of Hematology/Oncology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, 35294, USA.
Sajesan AryalDepartment of Medicine, Division of Hematology/Oncology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, 35294, USA.
Lixia ZhangDepartment of Medicine, Division of Hematology/Oncology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, 35294, USA.
Rui LuDepartment of Medicine, Division of Hematology/Oncology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, 35294, USA. ruilu1@uabmc.edu.ORCID http://orcid.org/0000-0003-1593-2612
University of Alabama at Birmingham · US

Funding

MEF2D-Mediated Transcriptional Control of Acute Myeloid LeukemiaR01CA259480 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Rui Lu · 2022 to 2026
$1.7M
NCI NIH HHS R01 CA259480
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukemia, Myeloid, AcuteGene RearrangementHumansMyeloid-Lymphoid Leukemia ProteinMyeloid-Lymphoid Leukemia Protein

Identifiers

PMID36309561
PMCPMC13158886
OpenAlexW4307532325

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.